Log in

NASDAQ:ANIPANI Pharmaceuticals Stock Price, Forecast & News

$30.89
-0.99 (-3.11 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$30.62
Now: $30.89
$32.27
50-Day Range
$29.93
MA: $31.26
$34.88
52-Week Range
$28.28
Now: $30.89
$86.96
Volume106,559 shs
Average Volume156,567 shs
Market Capitalization$374.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Read More
ANI Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANIP
Previous SymbolNASDAQ:BPAX
CUSIPN/A
Phone218-634-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$206.55 million
Cash Flow$8.11 per share
Book Value$17.59 per share

Profitability

Net Income$6.09 million

Miscellaneous

Employees299
Market Cap$374.08 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

How has ANI Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ANIP stock has decreased by 19.3% and is now trading at $30.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ANI Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ANI Pharmaceuticals.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for ANI Pharmaceuticals.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.15. The specialty pharmaceutical company earned $49.77 million during the quarter, compared to analysts' expectations of $49.40 million. ANI Pharmaceuticals had a negative net margin of 0.67% and a positive return on equity of 23.92%. View ANI Pharmaceuticals' earnings history.

What price target have analysts set for ANIP?

3 analysts have issued 12 month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $40.00 to $58.00. On average, they expect ANI Pharmaceuticals' stock price to reach $49.00 in the next year. This suggests a possible upside of 58.6% from the stock's current price. View analysts' price targets for ANI Pharmaceuticals.

Has ANI Pharmaceuticals been receiving favorable news coverage?

News coverage about ANIP stock has trended negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View the latest news about ANI Pharmaceuticals.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 559,500 shares, a decline of 10.1% from the June 15th total of 622,200 shares. Based on an average trading volume of 128,300 shares, the days-to-cover ratio is currently 4.4 days. Currently, 5.8% of the shares of the company are short sold. View ANI Pharmaceuticals' Current Options Chain.

Who are some of ANI Pharmaceuticals' key competitors?

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), AbbVie (ABBV), Cisco Systems (CSCO), Intel (INTC) and NXP Semiconductors (NXPI).

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:
  • Mr. Arthur S. Przybyl, Pres, CEO & Director (Age 62)
  • Mr. Stephen P. Carey, CFO & VP of Fin. (Age 48)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 56)
  • Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 47)

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $30.89.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $374.08 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.